<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01252498</url>
  </required_header>
  <id_info>
    <org_study_id>VCC1005</org_study_id>
    <nct_id>NCT01252498</nct_id>
  </id_info>
  <brief_title>Evaluation of the Role of Prostaglandins in Radiation-induced Mucositis</brief_title>
  <official_title>A Pilot Study to Evaluate the Role of Cyclooxygenase Pathway in Radiation Therapy and Chemoradiation Therapy Induced Mucositis in Head and Neck Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Vermont</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Vermont</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the role of cyclooxygenase pathways in radiation-induced and&#xD;
      chemoradiation-induced mucositis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Oral mucositis is a significant toxicity of radiation therapy and chemoradiation therapy in&#xD;
      head and neck cancer patients. However the mechanisms that induce such mucositis are not&#xD;
      completely understood. Previous work evaluating mucositis in bone marrow transplant patients&#xD;
      has suggested that prostaglandin levels may be associated with the appearance of mucositis.&#xD;
&#xD;
      The present study will measure the levels in saliva of the prostaglandins PGE2 and PGI2&#xD;
      before, during, immediately after, and several weeks after radiotherapy for head and neck&#xD;
      cancer. These salivary levels will be correlated with clinical observation of mucositis and&#xD;
      patient reporting of pain levels.&#xD;
&#xD;
      Improved understanding of the mechanism of mucositis may lead to the development of more&#xD;
      effective targeted agents to prevent this problem.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Salivary levels of PGE2 and PGI2 during and after radiotherapy</measure>
    <time_frame>10 weeks after initiation of therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Observed mucositis during and after radiotherapy</measure>
    <time_frame>10 weeks after initiation of radiotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reports of oral pain during and after radiation therapy</measure>
    <time_frame>10 weeks after initiation of radiotherapy</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">9</enrollment>
  <condition>Cancer of the Head and Neck</condition>
  <condition>Radiotherapy</condition>
  <arm_group>
    <arm_group_label>Radiotherapy</arm_group_label>
    <description>Patients receiving radiotherapy or chemoradiotherapy for head and neck cancer</description>
  </arm_group>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      Saliva will be collected at 4 time points before, during, immediately after, and several&#xD;
      weeks after radiotherapy for head and neck cancer.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients receiving radiotherapy or chemoradiotherapy for oral cancers. Consecutive patients&#xD;
        will be invited to participate.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven locoregional Stage 4 squamous cell carcinoma of the oral cavity,&#xD;
             larynx, oropharynx or hypopharynx&#xD;
&#xD;
          -  Receiving radiation therapy or chemoradiation therapy to the oropharynx&#xD;
&#xD;
          -  Older than 18 years old&#xD;
&#xD;
          -  ECOG performance status of 0-2&#xD;
&#xD;
          -  Life expectancy greater than 2 months&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous chemotherapy for this malignancy&#xD;
&#xD;
          -  Previous radiotherapy to the head and neck&#xD;
&#xD;
          -  Other cancer diagnosis within the last 5 years except for non-melanoma skin cancer or&#xD;
             non-metastatic prostate cancer&#xD;
&#xD;
          -  Patient taking NSAIDs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claire Verschraegen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Vermont/Fletcher Allen Health Care</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fletcher Allen Health Care</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>December 2, 2010</study_first_submitted>
  <study_first_submitted_qc>December 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2010</study_first_posted>
  <last_update_submitted>February 3, 2014</last_update_submitted>
  <last_update_submitted_qc>February 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Vermont</investigator_affiliation>
    <investigator_full_name>Claire Verschraegen</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Cancer of the head and neck</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Prostaglandins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Mucositis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

